|
1
|
Yonemori K, Kodaira M, Satoh T, Kudo T,
Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue K, et al:
Phase 1 study of olaratumab plus doxorubicin in Japanese patients
with advanced soft-tissue sarcoma. Cancer Sci. 109:3962–3970. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jain S, Xu R, Prieto VG and Lee P:
Molecular classification of soft tissue sarcomas and its clinical
applications. Int J Clin Exp Pathol. 3:416–428. 2010.PubMed/NCBI
|
|
3
|
Pervaiz N, Colterjohn N, Farrokhyar F,
Tozer R, Figueredo A and Ghert M: A systematic meta-analysis of
randomized controlled trials of adjuvant chemotherapy for localized
resectable soft-tissue sarcoma. Cancer. 113:573–581. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eilber FR, Giuliano AE, Huth JF and Morton
DL: A randomized prospective trial using postoperative adjuvant
chemotherapy (adriamycin) in high-grade extremity soft-tissue
sarcoma. Am J Clin Oncol. 11:39–45. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bramwell VH, Mouridsen HT, Santoro A,
Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas
D, Sylvester R, et al: Cyclophosphamide versus ifosfamide: Final
report of a randomized phase II trial in adult soft tissue
sarcomas. Eur J Cancer Clin Oncol. 23:311–321. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mytilinaiou M, Nikitovic D, Berdiaki A,
Papoutsidakis A, Papachristou DJ, Tsatsakis A and Tzanakakis GN:
IGF-I regulates HT1080 fibrosarcoma cell migration through a
syndecan-2/Erk/ezrin signaling axis. Exp Cell Res. 361:9–18. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ratan R and Patel SR: Chemotherapy for
soft tissue sarcoma. Cancer. 122:2952–2960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Gao LL, Tang MY, Feng BM, Pei YH
and Yasukawa K: Triterpenoids from Euphorbia maculata and their
anti-inflammatory effects. Molecules. 23:E21122018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patlolla JM and Rao CV: Triterpenoids for
cancer prevention and treatment: Current status and future
prospects. Curr Pharm Biotechnol. 13:147–155. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akihisa T, Tokuda H, Ichiishi E, Mukainaka
T, Toriumi M, Ukiya M, Yasukawa K and Nishino H: Anti-tumor
promoting effects of multiflorane-type triterpenoids and cytotoxic
activity of karounidiol against human cancer cell lines. Cancer
Lett. 173:9–14. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Banno N, Akihisa T, Yasukawa K, Tokuda H,
Tabata K, Nakamura Y, Nishimura R, Kimura Y and Suzuki T:
Anti-inflammatory activities of the triterpene acids from the resin
of Boswellia carteri. J Ethnopharmacol. 107:249–253. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sassa H, Kogure K, Takaishi Y and Terada
H: Structural basis of potent antiperoxidation activity of the
triterpene celastrol in mitochondria: Effect of negative membrane
surface charge on lipid peroxidation. Free Radic Biol Med.
17:201–207. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dirsch VM, Kiemer AK, Wagner H and Vollmar
AM: The triterpenoid quinonemethide pristimerin inhibits induction
of inducible nitric oxide synthase in murine macrophages. Eur J
Pharmacol. 336:211–217. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JS, Yoon IS, Lee MS, Cha EY, Thuong
PT, Diep TT and Kim JR: Anticancer activity of pristimerin in
epidermal growth factor receptor 2-positive SKBR3 human breast
cancer cells. Biol Pharm Bull. 36:316–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang H, Landis-Piwowar KR, Lu D, Yuan P,
Li L, Reddy GP, Yuan X and Dou QP: Pristimerin induces apoptosis by
targeting the proteasome in prostate cancer cells. J Cell Biochem.
103:234–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG:
The triterpenoid pristimerin induces U87 glioma cell apoptosis
through reactive oxygen speciesmediated mitochondrial dysfunction.
Oncol Lett. 5:242–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Byun JY, Kim MJ, Eum DY, Yoon CH, Seo WD,
Park KH, Hyun JW, Lee YS, Lee JS, Yoon MY and Lee SJ: Reactive
oxygen species-dependent activation of Bax and poly(ADP-ribose)
polymerase-1 is required for mitochondrial cell death induced by
triterpenoid pristimerin in human cervical cancer cells. Mol
Pharmacol. 76:734–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Costa PM, Ferreira PM, Bolzani Vda S,
Furlan M, de Freitas Formenton Macedo Dos Santos VA, Corsino J, de
Moraes MO, Costa-Lotufo LV, Montenegro RC and Pessoa C:
Antiproliferative activity of pristimerin isolated from Maytenus
ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro.
22:854–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okuno S, Edmonson J, Mahoney M, Buckner
JC, Frytak S and Galanis E: Phase II trial of gemcitabine in
advanced sarcomas. Cancer. 94:3225–3229. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keller F, Wilms H, Schultze G, Offerman G
and Molzahn M: Effect of plasma protein binding, volume of
distribution and molecular weight on the fraction of drugs
eliminated by hemodialysis. Clin Nephrol. 19:201–205.
1983.PubMed/NCBI
|
|
21
|
Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR
and Wu YC: Pristimerin induces caspase-dependent apoptosis in
MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer
Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mori Y, Shirai T, Terauchi R, Tsuchida S,
Mizoshiri N, Hayashi D, Arai Y, Kishida T, Mazda O and Kubo T:
Antitumor effects of pristimerin on human osteosarcoma cells in
vitro and in vivo. Onco Targets Ther. 10:5703–5710. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wyllie AH, Kerr JF and Currie AR: Cell
death: The significance of apoptosis. Int Rev Cytol. 68:251–306.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan
J: Pristimerin induces apoptosis in imatinib-resistant chronic
myelogenous leukemia cells harboring T315I mutation by blocking
NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 9:1122010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yousef BA, Hassan HM, Guerram M, Hamdi AM,
Wang B, Zhang LY and Jiang ZZ: Pristimerin inhibits proliferation,
migration and invasion, and induces apoptosis in HCT-116 colorectal
cancer cells. Biomed Pharmacother. 79:112–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie G, Yu X, Liang H, Chen J, Tang X, Wu S
and Liao C: Pristimerin overcomes adriamycin resistance in breast
cancer cells through suppressing Akt signaling. Oncol Lett.
11:3111–3116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Murgia M, Pizzo P, Sandoná D, Zanovello P,
Rizzuto R and Di Virgilio F: Mitochondrial DNA is not fragmented
during apoptosis. J Biol Chem. 267:10939–10941. 1992.PubMed/NCBI
|
|
29
|
Tamaki H, Harashima N, Hiraki M, Arichi N,
Nishimura N, Shiina H, Naora K and Harada M: Bcl-2 family
inhibition sensitizes human prostate cancer cells to docetaxel and
promotes unexpected apoptosis under caspase-9 inhibition.
Oncotarget. 5:11399–11412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brown JS and Banerji U: Maximising the
potential of AKT inhibitors as anti-cancer treatments. Pharmacol
Ther. 172:101–115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mu X, Shi W, Sun L, Li H, Jiang Z and
Zhang L: Pristimerin, a triterpenoid, inhibits tumor angiogenesis
by targeting VEGFR2 activation. Molecules. 17:6854–6868. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brasier AR: The NF-kappaB regulatory
network. Cardiovasc Toxicol. 6:111–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Connolly JL, Rodgers SE, Clarke P, Ballard
DW, Kerr LD, Tyler KL and Dermody TS: Reovirus-induced apoptosis
requires activation of transcription factor NF-kappaB. J Virol.
74:2981–2989. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu G, Wang X, Han Y and Wang P: Protein
arginine methyltransferase 5 promotes bladder cancer growth through
inhibiting NF-κB dependent apoptosis. EXCLI J. 17:1157–1166.
2018.PubMed/NCBI
|
|
39
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Potthoff RF and George SL: Flexible phase
I clinical trials: Allowing for nonbinary toxicity response and
removal of other common limitations. Stat Biopharm Res. 1:213–228.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cevatemre B, Erkısa M, Aztopal N, Karakas
D, Alper P, Tsimplouli C, Sereti E, Dimas K, Armutak EII, Gurevin
EG, et al: A promising natural product, pristimerin, results in
cytotoxicity against breast cancer stem cells in vitro and
xenografts in vivo through apoptosis and an incomplete autopaghy in
breast cancer. Pharmacol Res Mar. 129:500–514. 2018. View Article : Google Scholar
|
|
44
|
Ravasco P, Monteiro-Grillo I, Vidal PM and
Camilo ME: Cancer: Disease and nutrition are key determinants of
patients' quality of life. Support Care Cancer. 12:246–252. 2004.
View Article : Google Scholar : PubMed/NCBI
|
